Pfizer, the world's largest pharmaceutical group, has sold its Swedish-based diagnostic allergy-testing business to PPM Ventures and Triton, two European private equity houses, for $575m (€459m).

The deal brings to more than $44m the total fees earned by Lazard on five Pfizer deals in the past 18 months, according to estimates from Dealogic, the data provider.